01 1Risperdal
02 1Risperdal Consta
03 2Risperdal Consta
04 5Risperdal Consta
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 642
2019 Revenue in Millions : 688
Growth (%) : -7
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 592
2020 Revenue in Millions : 642
Growth (%) : -8
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 485
2021 Revenue in Millions : 592
Growth (%) : -18
Main Therapeutic Indication : Neuroscience/Mental Health
Currency : USD
2014 Revenue in Millions : -9.70%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Neuroscience and Mental Health
Currency : USD
2015 Revenue in Millions : 1,190
2014 Revenue in Millions : 970
Growth (%) : -18%
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2016 Revenue in Millions : 893
2015 Revenue in Millions : 970
Growth (%) : -8
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 805
2016 Revenue in Millions : 893
Growth (%) : -10
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 737
2017 Revenue in Millions : 805
Growth (%) : -8%
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 688
2018 Revenue in Millions : 737
Growth (%) : -7
LOOKING FOR A SUPPLIER?